Annual General Meeting held
The annual general meeting of DiaGenic ASA was held on 23 May 2013.
All proposals set out in the notice to the general meeting were approved.
In accordance with the recommendation from the Nomination Committee Hanne Skaarberg Holen was elected as Chairman of the board, and Patrik Dahlen, Ulrica Slåne and Tom Pike were elected as members of the board.
Leif Eriksrød (Alfred Berg Kapitalforvaltning) was elected as Chair of the Nomination Committee, and Andreas Lorentzen (Storebrand Kapitalforvaltning) and Inga Lise Lien Moldestad (Holberg Fondene) were elected as members of the Nomination Committee.
The minutes from the annual general meeting will be available at:
Paul de Potocki, CEO, Telephone: + 47 2324 8950
Ruben Ekbråten, CFO, Telephone: +47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com